leadf
logo-loader

Breakfast News - Quadrise Fuels, OKYO Pharma, Gfinity and more...

Kibo Energy PLC, the multi-asset Africa focused energy company, is seeking admission for its 100% owned UK subsidiary Sloane Developments Ltd , which will be renamed Mast Energy Developments PLC (MED), to the Standard List of the London Stock Exchange plc . Targeted for Q4 2020. The MED business strategy is to acquire and develop a portfolio of flexible small-scale power generation assets

Quadrise Fuels International PLC - Breakfast News -

18 August 2020

*A corporate client of Hybridan LLP

 

Dish of the day

No Joiners  Today

Off the menu

No Leavers Today.

What’s cooking in the IPO kitchen?

Kibo Energy PLC, the multi-asset Africa focused energy company, is seeking admission for its 100% owned UK subsidiary Sloane Developments Ltd , which will be renamed Mast Energy Developments PLC (MED), to the Standard List of the London Stock Exchange plc . Targeted for Q4 2020. The MED business strategy is to acquire and develop a portfolio of flexible small-scale power generation assets, exploiting a growth niche market in the UK for Reserve Power generation to balance out the national grid at critical times. 

 

TruSpine is a medical device company in the spinal device market. The Company is developing disruptive technologies for use in the spinal stabilisation market, commencing with the following three devices: Cervi-LOK - for the cervical and upper thoracic spine Faci-LOK - for the lumbar and lower thoracic spine, and GRASP Laminoplasty - a treatment for decompression of the spinal cord. AQSE Admission due 20 Aug

 

Banquet Buffet

Quadrise Fuels 2.93p  £30.3m (LON:QFI)

Update on entry of an MSAR® Commercial Trial Agreement (the Phase 1 CTA) with Greenfield Energy LLC,  the joint venture  between Valkor and Tomco Energy plc.

The Phase 1 CTA now entered into has a commercial value to Quadrise of US$150,000 and comprises the following activities that are planned to be completed during the remainder of 2020, subject to completion of preparatory works at the POSP facility by Greenfield prior to Quadrise personnel accessing the site in Utah later this year: Proof of Concept formulation and test work at the Quadrise Research Facility using oil samples supplied by Greenfield; loan of Quadrise MSAR® commercial production equipment and MSAR® test equipment and supply of MSAR® additives; and supply of specialist services to assist Greenfield in completing the commercial scale demonstration trial to produce over 600 barrels (100 tonnes) of power grade MSAR ® . Quadrise, Greenfield and its JV partners, Valkor and Tomco will continue to cooperate in good faith to agree the commercial terms of a conditional MSAR® licence and commercial supply agreement for the production of MSAR® fuel under Phase 2.  Such a conditional licence, which is now envisaged would be provided directly to Greenfield (rather than to Valkor and assignable to JVs as had been previously envisaged) will only be finalised upon, and following, inter alia, satisfactory results of the Phase 1 CTA, the agreement between the parties as to Phase 2 commercial terms and the entry of binding agreements.

 

OKYO Pharma 17.25p  £116m (LON:OKYO)

OKYO, the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, has raised an additional £1.4m through the issue of convertible loan notes. The proceeds of the CLNs, together with the £3.5m raised in July 2020 on similar terms will be used for working capital purposes.  OKYO intends to use the net proceeds received from the CLNs, to further the development of its clinical pipeline. The Company has now raised £5.37m since the end of the financial year on 31 March 2020, substantially enhancing cash on hand for advancement of the clinical development program, details of which were included in the announcement of annual result yesterday. The Company now intends to progress a dual listing of its existing equity share capital on NASDAQ (subject to the required regulatory approvals.

 

Gfinity 3.9p  £29m (LON:GFIN)

Gfinity continues to grow its user base, whilst increasing its lucrative US audience and adding new partnerships including Steel Series and TopCashBack. Gfinity Digital Media is one of the fastest-growing revenue streams for the Company.  Since the partnership with Venatus was implemented in mid-April 2020, it had delivered close to £200,000 through on-site advertising by the end of July. In addition, Gfinity Digital Media has been selected to deliver a growing number of repeat advertising campaigns for high-profile publishers, with a strong pipeline of direct campaigns already secured and running in August. For example, following a competitive tender, the Danish gaming peripherals company Steel Series chose the Company's web channels as a location to promote their collection of headsets. The partnership was brokered between Venatus and Gfinity's direct sales team.

 

Enteq Upstream 12.75p  £8.6m (LON:NTQ)

On 17 August 2020, Enteq received a Purchase Order and confirmation of a cash deposit payment in respect to a conditional contract valued at $0.9m for equipment to deploy in Saudi Aramco's drilling operations. The contract is with Enteq's new strategic partner in the Kingdom of Saudi Arabia, Sawafi Aljazeera Oilfield Products and Services Co. Ltd Sawafi. This order is for the recently released XXH product, an ultra-high durability version of Enteq's Measurement While Drilling technology. Future opportunities are anticipated for Enteq's technology partner equipment and new product releases.

 

Karelian Diamonds 4.3p  £1.8m (LON:KDR)

£420k placing at 4p.  The net proceeds of the Placing will be used by the Company to explore the acreage surrounding the Lahtojoki diamond deposit and to expedite its technical assessment of the deposit, for exploration in the Kuhmo region of Finland where the Company has discovered a green diamond in till and for general working capital purposes.

 

MaxCyte 343p  £231m (LON:MXCT)

CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11. New parallel cohort will broaden evaluation of MCY-M11 in patients through inclusion of a preconditioning regimen and multiple dosing cycles. Clinicians at Massachusetts General Hospital and Hackensack University Medical Center will join those at the National Cancer Institute and Washington University at St. Louis to evaluate MCY-M11 in the ongoing Phase I clinical trial. To date, ongoing first-in-human study has demonstrated promising tolerability of MCY-M11 and feasibility of rapid, one-day autologous manufacturing.

 

Eurasia Mining  23p  £627m (LON:EUA)

General update and successful completion of a US$10m equity placing with institutional investors at a price of 22.5p per share, which is equal to the closing price on 17 August 2020. West Kytlim update: Production is ongoing at site and unaffected by Covid-19 with payments for metal already received. Monchetundra update: The Flanks application advanced through all federal bodies including FSB and Ministry of Defence and is awaiting license issuance. Extensive prior drilling campaigns with c.48,000m drilled at NKT, a part of the Flanks application.

 

Essensys 152.5p  £80.4m (LON:ESYS)

The provider of mission critical software-as-a-service (SaaS) platforms and on-demand cloud services to the flexible workspace industry, announced an unaudited pre-close trading update for the financial year ended 31 July 2020. Revenue for the year was in line with market expectations at £22.4m, an increase of 9% (FY19: £20.6m).   Recurring revenue increased by 18% to £19.3m (FY19: £16.3m) and represented 86% of revenue in the year (FY19: 79%).  Adjusted EBITDA is expected to be in line with market expectations. The Group's US business continued to grow strongly with year-on-year recurring revenue increasing 43% to £8.0m from £5.6m in FY19.

 

Coinsilium 2.35p  £3.2m (AQSE:COIN)

The Blockchain, DeFi and Crypto Finance venture operator, announced that its joint venture company  with IOV Labs Ltd  in Singapore has signed a Memorandum of Understanding with Vietnam-based RedFOX Labs Joint Stock Company to build fast scaling internet businesses on and for the RSK Blockchain in the Southeast Asian region. The MoU is expected to lead to formal commercial and technical agreements whereby RedFOX will migrate its applications to the RSK blockchain and become a hub for RSK blockchain technology expertise in Vietnam under the IOV Asia JV umbrella.

 

Arricano Real Estate 0.3p  £31m (LON:ARO)

Arricano has agreed a reduction in interest rate from 10.75% to 9.75% per annum on the USD12m loan agreement with Tascombank JSC repayable in June 2024.

 

If you would like to unsubscribe, please email [email protected] with “unsubscribe me”.

 

Head Chef

Derren Nathan

0203 764 2344

[email protected]

Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II              Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Quadrise Fuels International PLC named herein, including the promotion by the Company of Quadrise Fuels International PLC in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma presents at the Proactive One2One virtual conference

Amryt Pharma's LON:AMYT) Rory Nealon presents at the Proactive One2One virtual conference. Amryt Pharma is a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of people with rare and orphan diseases. The company...

5 hours, 29 minutes ago

12 min read